Janknegt R A
Department of Urology, University Hospital Maastricht, The Netherlands.
Scand J Urol Nephrol Suppl. 1995;168:21-7.
Alpha adrenergic receptors in prostatic smooth muscle play a major role in the development of bladder outlet obstruction in patients with benign prostatic hyperplasia (BPH). As a result, alpha adrenoceptor antagonists have been used increasingly in the treatment of this condition. Doxazosin is a selective alpha 1 antagonist with a long half-life and gradual onset of action, which make it suitable for once-daily treatment. In placebo-controlled trials, doxazosin has been shown to improve maximum and mean urine flow rates, reduce urethral resistance and bladder contractility, and improve obstructive and irritative symptoms. These changes develop within a few weeks of starting treatment and are maintained during long-term treatment over periods of years. Doxazosin is also well tolerated; adverse events are generally mild or moderate and do not interfere with treatment. These features combine to make doxazosin an effective, convenient and well-tolerated treatment for the management of patients with BPH.
前列腺平滑肌中的α肾上腺素能受体在良性前列腺增生（BPH）患者膀胱出口梗阻的发生中起主要作用。因此，α肾上腺素能受体拮抗剂越来越多地用于治疗这种疾病。多沙唑嗪是一种选择性α1拮抗剂，半衰期长，起效缓慢，这使其适合每日一次给药。在安慰剂对照试验中，多沙唑嗪已被证明可提高最大尿流率和平均尿流率，降低尿道阻力和膀胱收缩力，并改善梗阻性和刺激性症状。这些变化在开始治疗后的几周内出现，并在长达数年的长期治疗中持续存在。多沙唑嗪的耐受性也很好；不良事件通常为轻度或中度，不影响治疗。这些特性使多沙唑嗪成为治疗BPH患者的一种有效、方便且耐受性良好的药物。
